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Abstract 
Cardiac dysfunction has an increased prevalence in diseases complicated by liver cirrhosis 
such as primary biliary cholangitis and primary sclerosing cholangitis. This observation has 
led to research into the association between abnormalities in bile acid metabolism and cardiac 
pathology.  Approximately 50% of liver cirrhosis cases develop cirrhotic cardiomyopathy.  
Bile acids are directly implicated in this, causing QT interval prolongation, cardiac 
hypertrophy, cardiomyocyte apoptosis and abnormal haemodynamics of the heart.  Elevated 
maternal serum bile acids in intrahepatic cholestasis of pregnancy, a disorder which causes an 
impaired feto-maternal bile acid gradient, have been associated with fatal fetal arrhythmias. 
The hydrophobicity of individual bile acids in the serum bile acid pool is of relevance, with 
relatively lipophilic bile acids having a more harmful effect on the heart.  Ursodeoxycholic 
acid can reverse or protect against these detrimental cardiac effects of elevated bile acids. 
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1.1 Bile acid synthesis 
Bile acids (BAs) are synthesised in the liver via cholesterol catabolism in a multi-enzymatic 
pathway; the rate- limiting step being the initial conversion by the cytochrome P450 enzyme 
CYP7A1.  The primary BAs cholic acid (CA) and chenodeoxycholic acid (CDCA) are 
subsequently conjugated in the liver with amino acids taurine or glycine. Subsequent to 
secretion into the gut during food digestion, intestinal microbiota cause their deconjugation 
and dehydroxylation via 7-alpha-dehydroxylase, forming the secondary BAs deoxycholic 
acid (DCA) and lithocholic acid (LCA) respectively [1]. The majority of BAs are reabsorbed 
in the intestine and return to the liver for re-uptake via the portal vein, a process known as the 
enterohepatic circulation. BAs characteristically have an amphipathic nature and their 
hydrophobicity is linked to their conjugation with amino acids.  Conjugated BAs are more 
hydrophilic, and their resulting decreased membrane permeability causes a reduction in 
cytotoxic potential [2].  
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Figure 1: Bile acid (BA) synthesis and signalling: Primary BAs are synthesised and 
conjugated in the liver and are  deconjugated and dehydroxylated in the intestine to form 
secondary BAs. Their signalling occurs through various pathways, and highlighted here is the 
nucleus-based activation of Farnesoid X receptor (FXR and the enterocyte-expressed Takeda 
G protein-coupled receptor (TGR5) by primary and secondary BA ligands as well as the 
nucleus-based activation of vitamin D receptor (VDR) by LCA. 
 
1.2 Electrical conduction and the mechanics of the heart 
Normal cardiac function requires the co-ordination of electrical activity and mechanical 
contraction of the ventricles and atria of the heart. This is initiated via the spontaneous 
generation of an action potential by the sino-atrial node, propagating to the atrioventricular 
node via the right and left atria, causing the atria to contract, and then for blood to fill the 
ventricles that are in their relaxed or diastolic phase. Ventricular depolarisation occurs, and 
once ventricular pressure surpasses atrial pressure, the atrioventricular valves close, causing a 
state of isovolumetric contraction in the ventricles.  The continuation of this signal through 
the distal fibres of the atrioventricular node (known as the bundle of His) subsequently cause 
the right and left ventricles to contract, and this electrical signal is then propagated via the 
Purkinje fibres to cardiomyocytes, allowing the ejection of blood by the ventricles, known as 
ventricular systole.  A state of isovolumetric relaxation then occurs, forming the end of one 
cardiac cycle and reintroduction into the diastolic phase of the ventricles.  The cardiac cycle 
can be observed using electrocardiography (ECG), where the QRS complex which results 
from recording electrical activity represents the stages of ventricular depolarisation. The PR 
interval refers to the time taken from atrial depolarisation to ventricular depolarisation and 
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the QT interval refers to the time taken for ventricular depolarisation and repolarisation to 
take place.  Abnormalities in the length of either interval can be indicative of atrial or 
ventricular tachyarrhythmias respectively [3, 4].    
 
 
Figure 2: The blood flow through the heart during the cardiac cycle in correspondence with 
the QRS complex observed in electrocardiography: (A) Atrial filling during atrial diastole (B) 
Atrial systole and ventricular filling (C) Ventricular isovolumetric contraction (D) 
Ventricular systole and ejection of blood from the ventricles.  The measurement of the PR 
and QT interval values using the QRS complex is also indicated in (A).   
 
 
1.3 Bile acid receptors are expressed in the heart 
It is now known that receptors which mediate BA signalling are also expressed in 
cardiovascular tissue. The nuclear BA receptor farnesoid-X receptor (FXR), whose main 
ligands are the primary BAs has been shown to be expressed in the vasculature [5].  
Activation of vasculature-specific FXR improves lipid profiles and influences vascular 
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tension, thereby resulting in an anti-atherosclerotic effect [5, 6].  Low levels of FXR 
expression were detected in neonatal cardiomyocytes; however no functional response of 
these receptors was induced [7].  Recent work by Pu et al has also demonstrated the presence 
of FXR in adult cardiomyocytes and cardiac tissue, and activation of cardiomyocyte FXR via 
in vitro CDCA administration significantly induced FXR mRNA expression.  In vitro 
administration of CDCA also resulted in a dose and time-dependent apoptotic response in 
these cells.  Opening of the Mitochondrial Permeability Transition Pore (MPTP), a protein 
involved in apoptotic signalling and associated with heart failure, was also found to be 
induced by FXR activation [8, 9].  Potentially clinically relevant data show that FXR 
expression was significantly upregulated in ischaemic cardiac tissue in rats and inhibition of 
FXR reduced the size of insult, suggesting that FXR plays an important role in mediating 
cardiac apoptosis and injury [8].   
 
Expression of the vitamin D receptor (VDR) has been localised in the t-tubules of 
cardiomyocytes [10].  In addition to vitamin D, the secondary bile acid LCA is known to be a 
ligand for this receptor. Cardiomyocytes isolated from vdr
-/-
 mice have increased rates of 
contraction and activation of the receptor in wild type mice also resulted in altered 
contractility when vitamin D was used as a ligand rather than LCA [10].  Vitamin D exposure 
also altered proliferation and morphology of cardiomyocytes [11].  Selective deletion of the 
VDR in cardiomyocytes resulted in myocyte enlargement, cardiac hypertrophy, systolic and 
diastolic dysfunction [12].  There is therefore evidence of VDR expression and functional 
activity of relevance to normal cardiomyocyte function. However, whether these pathways 
are also influenced by LCA-liganded VDR has not been demonstrated.    
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The expression of Takeda G protein-coupled receptor 5 (TGR5), also known as G protein-
coupled bile acid receptor 1 GPBAR1, mRNA has been identified in moderate levels in 
human, rabbit and bovine heart tissue, as well as mouse tissue and cardiomyocytes at a 
protein level [13-15].  Although TGR5 expression in the heart has been demonstrated, its 
function remains unknown, however, certain studies have shown that TGR5 does respond to 
BA administration.  Mouse cardiomyocyte-specific TGR5 responded to administration of 
taurochenodeoxycholic acid (TCDCA) and LCA by downregulating glycogen synthase 
kinase-3β (GSK3β) and upregulating protein kinase B (AKT), which are known to be 
associated with cardiac hypertrophy [15].  In addition, TGR5 expressed in the endothelium of 
the bovine aorta produced Nitric Oxide (NO) in a dose-dependent manner in response to 
taurolithocholic acid (TLCA) administration [16]. 
 
Experiments on neonatal cardiomyocytes demonstrated the ability of taurocholate (TCA) to 
mediate muscarinic M2 receptor-induced alterations in contractility [7] (see later).   
 
 
1.4 Cholestatic liver disorders are associated with impaired cardiovascular function 
Total serum bile acid (TSBA) concentrations are known to increase in patients with liver 
dysfunction [17].   In general, it has been observed that patients with liver disorders have 
cardiac and haemodynamic changes with increased cardiac output and decreased vascular 
resistance [18]. The cardiotoxicity of BAs was observed as early as 1863 with the discovery 
that bile acid administration induced bradycardia and eventually cause cardiac arrest [19]. 
The relationship between BAs, liver disorders and cardiac dysfunction was initially 
investigated in detail in 1953 by Kowalski et al, who observed that patients with liver 
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cirrhosis had a prolonged QT interval [20].  Further observations of cirrhotic patients coupled 
with the knowledge that BAs are significantly elevated during liver dysfunction gave rise to 
the suggestion that BAs are one of the components in the mechanism of cardiac dysfunction. 
 
The two most characterised cholestatic liver disorders are Primary Biliary Cholangitis (PBC) 
(also known as primary biliary cirrhosis) and Primary Sclerosing Cholangitis (PSC), both of 
which have been associated with poor cardiovascular function. PBC, a disorder more 
commonly observed in women, results from the lymphocytic inflammation and later 
destruction of intrahepatic bile ducts, leading to cirrhosis and an increase in TSBA 
concentrations [21].  Similarly, PSC, a disorder more commonly seen in men, results in the 
inflammation of the biliary epithelium of the intrahepatic and extrahepatic bile ducts [22].  
Currently, the primary FDA approved drug for treatment of both these disorders is 
ursodeoxycholic acid (UDCA).  UDCA is a relatively hydrophilic BA which is thought to 
displace more hydrophobic BAs in the BA pool and therefore shift the composition to a less 
toxic one; the importance of which will be discussed later in this review [22-24]. 
 
 
1.4.1 Primary Biliary Cholangitis and Primary Sclerosis Cholangitis increase the risk of 
cardiovascular disease 
There is a known association between patients with cholestasis and an impairment in 
cardiovascular function, and several population studies have sought to highlight these 
associations and define the alterations in risk. 
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The relative risk (RR) of cardiovascular disease after onset of PSC is 3.34, but this is 
primarily arterial or venous disease [25].  PSC has also been demonstrated to cause 
dyslipidaemia and changes in low density lipoprotein (LDL) cholesterol; however, lipid 
profiles do not appear to correlate with risk of cardiovascular events.  This may be attributed 
to the high concentration of lipoprotein-X (LP-X) found in PSC patients, an abnormal LDL 
that has been shown to have anti-atherosclerotic effects.  However, the small sample size in 
the study suggests a lack of conclusive data to establish the role of dyslipidaemia and further 
investigation is required  [26].  A single case study has shown that a patient who has been 
diagnosed with PSC and epilepsy had impaired ventricular function, specifically ventricular 
tachycardia with a short coupling interval, although the aetiology for this disorder was 
unknown [27].  
 
In contrast to PSC, there are more data regarding the link between PBC and cardiovascular 
dysfunction.  In the most recent study, the RR of cardiac events in comparison to controls 
was found to be 2.2 [23].  Patients with PBC have dyslipidaemia with increased levels of 
serum cholesterol, primarily LP-X, that decrease in later stages of the disease.  However this 
again is not associated with an increased risk of cardiovascular events, a result which again 
may be attributed to small sample size or the anti-atherosclerotic effects of LP-X [28].   
 
Earlier studies showed that patients with PBC have significant prolongation of the corrected 
QT (QTc) interval [29]. Impedance cardiography has shown that PBC patients have an 
abnormal left ventricular (LV) ejection time in response to tilting from a supine to upright 
position. Interestingly, this response was not seen in PSC patients [30].  Magnetic Resonance 
Spectroscopy also indicated significant reduction of markers of cardiac muscle energy 
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function [30].  Studies have also shown that PBC results in a significantly reduced heart rate 
variability (HRV) and baroreflex sensitivity, both of which were associated with the 
incidence of fatigue, a  commonly observed symptom in patients with PBC [31].  Patients 
with early-stage PBC had reduced thoracic fluid content which in turn affected myocardial 
contractility and diastolic function; this was independently associated with markers of cardiac 
inotropy or contractility [32].    A case report also described right ventricular dysfunction in 
one patient 7 years after diagnosis with PBC [33]. 
 
Alagille syndrome, an autosomal dominant disorder caused by a mutated JAG1 or NOTCH2 
gene, results in a cholestatic state due to the lack of interlobular ducts in the liver. Patients 
with this syndrome commonly present with cardiac murmur and are also diagnosed with 
Tetralogy of Fallot (TOF), the most common form of cyanotic congenital heart disease [34].  
TSBA concentrations in patients with TOF have also been correlated with right ventricular 
function [35].     
 
Biliary atresia is a rare disorder that presents in infancy, however is the most common cause 
of liver transplants and cirrhosis in that age group [36].  Infants with biliary atresia awaiting 
liver transplantation have been shown to exhibit pathologies in cardiac structure and function 
including significant increases in LV and septal wall thickness and LV shortening fraction.  
72% of infants in one study displayed features of cirrhotic cardiomyopathy prior to 
transplantation, a syndrome which is described in more detail in the next section [37].  
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1.5 Cirrhosis can result in the development of Cirrhotic Cardiomyopathy 
Cholestatic disorders can eventually result in cirrhosis of the liver [38]. It is estimated that 
approximately half of all cases of liver cirrhosis result in the development of cirrhotic 
cardiomyopathy (CC), a disorder characterised by systolic and diastolic dysfunction, 
morphological changes and abnormalities in the electrophysiology of the heart [39].   
 
CC is caused in part by electrophysiological abnormalities; including the inability to respond 
to certain pharmacological stimuli, the disruption of the contraction response of 
cardiomyocytes to electrical excitation and a prolonged QT interval. The latter symptom in 
particular delays ventricular repolarisation and lays the groundwork for a possible ventricular 
arrhythmia to occur.  A prolonged QT interval is associated with increased risk of sudden 
death and mortality due to this potential to cause arrhythmias [40].  
 
A morphological abnormality that has been observed with different degrees of severity in 
cirrhotic patients of one study is left ventricular hypertrophy, which has been shown to 
eventually lead to diastolic dysfunction [41]. The most common electrophysiological 
abnormality seen in patients with CC is an increase in QT interval length compared to non-
cirrhotic controls [40] 
 
It is thought that numerous factors are involved in the development of CC, however there is 
evidence that BAs play an important role.  The relationship between BA metabolism and 
cardiac dysfunction or CC has been determined with both in vitro systems and experimental 
models in intact animals.  Direct effects of BA acid exposure can be observed in vitro using 
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isolated cardiomyocytes and muscle strips.  The indirect effect of BA metabolism can also be 
determined through animal models of cirrhosis which are known to result in CC. Bile duct 
ligation (BDL) is the primary method to produce such a model but other models of cirrhosis 
can be generated by other methods such as portal vein stenosis, carbon tetrachloride (CCl4) 
or 3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC) feeding [15, 42].   Important data on 
the effects of impaired BA metabolism on the heart has also been identified in humans with 
cholestatic liver disorders as described above for PBC and PSC. 
 
 
1.5.1 Bile duct ligation allows mechanisms of Cirrhotic Cardiomyopathy to be 
uncovered 
The pathogenesis of CC is multi-factorial and complex, however manually obstructing the 
bile duct itself has allowed experimental investigation into some of the underlying 
mechanisms involved. BDL, mainly in the rat and mouse, results in rodent models of what we 
now know as CC, and has therefore allowed the investigation into the relationship between 
BA metabolism and the associated cardiovascular phenotype.   
 
Early experiments observed that BDL of rats causes a decrease in heart rate and significant 
biochemical changes in the serum, with increased bilirubin peaking at 5 days post ligation.  
ECG analysis has also shown prolongation of PR and QT intervals [43, 44]. Aside from the 
rat model, CC via BDL has also been shown in dogs, which also display features 
characteristic of CC such as increased cardiac output and electrophysiological abnormalities 
[45]. 
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The importance of apoptotic pathways in contributing to CC was identified by Nam et al, 
whose studies of cardiomyocytes isolated from BDL rats showed a significant increase in 
apoptotic markers e.g. poly ADP-ribose polymerase (PARP) and also an increase in systolic 
and diastolic function upon administration of anti-FasL antibody, an inhibitor to the apoptotic 
Fas pathway.  This effect was not observed in cardiomyocytes isolated from their sham 
counterparts.  This evidence suggests that myocardial apoptosis can be induced by BDL and 
will in turn lead to CC [46]. Further investigation has identified the role of NO in 
cardiomyocyte apoptosis.  Hearts harvested from BDL mice have increased rates of apoptosis 
and morphological abnormalities and inhibition of NO synthase in these mice resulted in 
improvement of both of these parameters, suggesting that it acts as the mediator [47].  These 
results are in agreement with studies which show administration of increased concentrations 
of DCA and CDCA on isolated vascular endothelial cells in vitro results in the increase of 
NO production via intracellular Ca
2+
 signalling, investigated using whole cell patch clamping 
[48].   Increased apoptosis was also observed in BDL mice using a terminal transferase 
deoxyuridine triphosphate nick end labelling assay (TUNEL), and this was significantly 
decreased with the addition of the endogenous opioid naltrexone, suggesting that blocking of 
opioid receptors can modulate apoptosis, however this did not appear to affect LV diastolic 
function [49]. 
 
BDL appears to induce significant haemodynamic changes in the rat including increased 
cardiac output, hypotension and basal bradycardia.  These changes were reversed upon 
administration of cholestyramine, an intestinal BA sequestrant, suggesting that BAs have a 
direct role in the pathogenesis of these parameters [50]. The hormone erythropoietin has also 
been shown to have a cardioprotective effect on BDL rats, reversing systolic and diastolic 
dysfunction and lowering oxidative stress via the decrease of expression of contractile 
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inhibitory factor TNFα [51]. BDL-induced cirrhosis in rats also has an inhibitory effect on 
cardiac mitochondria, reducing capacity for oxygen consumption and ATP synthesis, [52, 
53].   
 
Ma et al have demonstrated that BDL rats have decreased cardiac membrane fluidity which 
results in beta adrenergic dysfunction and inability to produce cAMP, resulting in blunted 
contractile ability [54, 55]. The expression of titin and collagen (regulators of passive tension 
in cardiac muscle) are altered in BDL rats, suggesting that abnormal expression of these 
proteins contribute to contractile dysfunction in CC [56].  Isolated monocytes from BDL rats 
have been shown to reduce cardiomyocyte contractility in vitro [57, 58].  Inducing 
haemorrhage in BDL rats significantly reduced LV contractility, a change that was quickly 
reversed in controls.  This was associated with the release of endocannabinoids, a known 
component of the stress-response system in the heart, suggesting a mechanism of why CC 
causes impaired cardiovascular response [57].  Previous studies have shown that cytokines 
such as interleukin-1beta (IL-1β) mediate cardiomyocyte contractility via nitric oxide 
synthase-2 (NOS2) in BDL-induced cirrhosis [59].   
 
Murine models of BDL-induced CC have therefore highlighted several different mechanisms 
by which cirrhosis causes cardiovascular complications. The explicit effect of BA 
metabolism on cardiac function can also be observed in murine models via in vitro and in 
vivo experiments where direct BA exposure has been performed. 
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1.5.2 Exposure of the heart to relatively hydrophobic bile acids results in cardiac 
dysfunction  
BAs can be directly administered in murine models to expose their direct role in cardiac 
function.  In these experiments, it is important to consider the specific species of BAs, as 
relative hydrophobicity plays a role in determining their effect. 
 
Early in vitro experiments with cardiomyocytes provided the initial impetus for determining 
the effect of bile acids on the heart.  Incubation of sera from jaundiced rats on cultured 
cardiomyocytes caused their contractions to slow down and eventually cease; an effect also 
seen with DCA treatment in isolation. This gave rise to the hypothesis that DCA was the 
component in jaundiced sera causing the cardiomyocyte phenotype [60].  
 
In addition to the BDL experiments described above, Joubert et al also found that injection of 
CA resulted in dose-dependent negative chronotropic effects.  Bradycardia was observed in 
most rats at doses of >10mg/kg, an effect that was slightly reduced by removal of the vagal 
nerve and increased when administered in the vein rather than the artery, giving rise to the 
suggestion that BAs cause both direct and vagally-mediated hypotensive effects [43]. 
 
Binah et al demonstrated that in vitro administration of primary and secondary BAs at 
concentrations as low as 10nmol/L on rat ventricular muscle resulted in negative inotropic 
effects, including a reduction in active tension as well as the rate of tension activation and 
relaxation.  This corresponded with a reduction in the duration of the ventricular action 
potential.  Incubation with sodium taurocholate resulted in changes in the inward calcium 
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(Ca
2+
) and outward potassium (K
+
) currents that generate the contraction action potential, 
suggesting that BAs affect membrane potential and hence induce alterations in inotropism 
[61]. 
 
The effect of sodium taurocholate on the sino-atrial node in vitro has been studied previously 
in the rabbit.  Physiological-mimicking concentrations of >30µmol/L had effects on the 
action potential of the sino-atrial node, decreasing the time to peak. Higher concentrations of 
>100µmol/L decreased the rate of diastolic depolarisation and resulted in prolonged 
bradycardia.  Both inward Ca
2+
 and outward
 
K
+
 currents of the sino-atrial node were also 
slowed, in agreement with the earlier results seen by Binah et al [62]. 
 
Recent detailed studies in murine models have further linked elevated BAs and CC and 
investigated the underlying mechanisms. Inducing biliary fibrosis, cholestasis and 
cholanaemia in mice via DDC feeding resulted in elevated markers of cardiac dysfunction, 
including the decrease of heart rate and cardiac mass and increase in ejection fraction, all of 
which correlated with the increase in circulating BA levels. In addition, expression of genes 
which regulate fatty acid oxidation (FAO) and are induced in stress response were correlated 
with BA concentration. CA feeding in bile salt export pump (BSEP) deficient mice also 
demonstrated this effect, confirming a role for BAs as important mediators of cardiac 
dysfunction.  Reversal of liver injury using a normal chow diet showed a recovery in 
biochemical, structural and electrocardiographic abnormalities [63]. 
 
More recently the in vivo and in vitro effects of BA administration in Fxr and Shp-deficient 
mice have been studied. Double knock out (DKO) mice (lacking both these genes required 
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for BA homeostasis) exhibited cardiac hypertrophy, reduced cardiac output, bradycardia and 
prolonged QTc and PR intervals together with elevated markers of myocardial remodelling 
and injury; thus validating this strain as another model of CC.  Injection of 100mg/kg of TCA 
and LCA mimicked these effects in wild type mice, as did acute administration of these BAs 
via perfusion.  In vitro CDCA treatment of cardiomyocytes (isolated from wild type mice) at 
pathological concentrations led to metabolic dysfunction and the suppression of expression of 
fatty oxidation regulatory and glucose oxidation genes, a term they coined “cholecardia”, a 
pathology which could explain the contractile disturbances in diseases associated with 
elevated serum BA levels.  This effect was also seen in vivo and ex vivo via DKO mice and 
perfusion of DKO mouse hearts respectively.  Reducing the BA pool in DKO mice via 
cholestyramine resulted in the restoration of cardiac function, including heart rate, cardiac 
output and systolic and diastolic function [64].  
 
Further evidence of the effect of BAs on cardiac mitochondria has been shown by Ferreira et 
al, who isolated cardiac mitochondria from wild type rats and exposed them to various 
physiological concentrations of BAs in vitro.  Exposure to relatively more hydrophobic BAs 
(LCA, DCA and CDCA) resulted in alterations in mitochondrial energetics, including a 
decrease in the mitochondrial respiratory ratio and membrane potential, resulting in MPTP 
activation.  The relatively hydrophilic BAs glycochenodeoxycholic acid (GCDCA), 
taurodeoxycholic acid (TDCA) and glycoursodeoxycholic acid (GUDCA) had less of an 
effect. GUDCA was the most hydrophilic BA tested and had the lowest mitochondrial 
toxicity index [53].   
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Zavecz and Battarbee compared the effect of CA in mouse ventricular muscle strips in vitro 
to the in vivo cirrhosis effect induced by portal vein stenosis (PVS) in rats.  They found that 
administration of CA caused similar reductions in contractile tension as were seen in PVS 
rats at concentrations as low as 1nmol/L. Administration of UDCA did not increase this 
tension in combination with CA; however chronic gavage of UDCA in PVS rats partially 
reversed the decrease in contractile tension.  This suggests that the phenotype reversal upon 
UDCA treatment was due to displacement of hydrophobic BAs in the BA pool of the PVS 
rats rather than direct exposure [42].  CA exposure also resulted in decreased beta-adrenergic 
response, decreased cAMP production, reduced concentration of intracellular stores of 
calcium and reduced sodium-calcium exchange activity, all of which are associated with 
cardiomyocyte contraction [42]. 
 
It has also been shown that TCA, GCA and GCDCA cause a dose-dependent induction of 
arrhythmic contractions in adult human atrial trabeculae, with TCA in particular causing a 
significant induction in arrhythmias at concentrations of ≥30µmol/L in vitro; corresponding 
with the TSBA concentrations seen in patients with cholestasis [65]. UDCA appeared to 
reverse this atrial fibrillation, corresponding with the attenuating effect seen in the 
experiments described above.  Rainer et al also showed via logistic regression analysis of 250 
patients who had heart failure that hydrophobic BA concentrations act as predictor of atrial 
fibrillation [65]. 
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Figure 3: The pathogenesis of cirrhotic cardiomyopathy (CC): Development of CC is 
complex and multifactorial, however defects in the regulation of bile acid metabolism have 
been demonstrated to heavily influence the development of CC characteristics. 
 
The above studies illustrate the direct effect of BA exposure on cardiac function, as well as 
demonstrating the link between the magnitude of these effects and the hydrophobicity of the 
BAs involved. Desai et al showed that CC can be reversed in mouse models upon 
normalisation of BA concentrations and recovery of DDC-induced cirrhosis using normal 
chow feeding.  UDCA appears to have a protective effect on cardiomyocytes and atrial 
trabeculae in vitro, and the effect on neonatal cardiomyocytes will be discussed later in this 
review.  The effect of UDCA on adult cardiac function in vivo has also been documented, as 
described below: 
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1.5.3 UDCA has a protective effect in adult cardiac disease 
The proven efficacy and safety of UDCA in hepato-biliary disease has made it an 
increasingly popular drug, and this has promoted exploration of the potential benefit of its use 
in other disease areas, including adult cardiac conditions such as myocardial infarction and 
atherosclerosis.  
 
Sudden cardiac death (SCD), caused by acute myocardial infarction (AMI), is a frequent 
cause of death in developed countries [66-69]. Typically caused by atherosclerosis and 
thromboembolic events; occlusion of a coronary artery results in complete or partial ischemia 
of the downstream myocardial tissue, followed by the development of an infarction. It is well 
known that restoration of the blood flow to previously ischemic myocardium results in a 
range of reperfusion-associated pathologies named ‘ischemia-reperfusion (IR) injury’. This 
has a considerable impact on health and society, not only due to the acute-phase mortality 
caused, but also because of the long-time morbidity and mortality [70]. Based on the 
protective effects of UDCA observed in liver IR injury, effects on the heart have been studied 
and, interestingly, UDCA has been found to prevent IR injury and cardiac infarction. Pre-
clinical studies have been conducted by Lee et al. in 1999 and Rajesh et al. in 2005 [71, 72]. 
In the isolated heart perfusion model, Lee et al. showed that UDCA (80-160µ) reduces IR 
damage following 30 minutes of global ischemia. The beneficial effects included improved 
left-ventricular diastolic pressure (LVDP), enhanced contractile function and reduced release 
of lactate dehydrogenase (LDH), a well-known marker of cellular integrity [71]. Later, 
Rajesh et al. evaluated the effects of UDCA pre-treatment on ischemia-reperfusion in an 
anaesthetized rat model. Animals were treated either with UDCA (40mg/kg) or vehicle for 30 
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minutes prior to left-coronary artery occlusion for 180 minutes, followed by a 180 minute 
period of reperfusion. From histological analysis it emerged that animals treated with UDCA 
had a reduced infarcted area following reperfusion. This was proposed to be mainly due to 
the capacity of UDCA to inhibit the mitochondrial permeability transition pore via activation 
of the phosphatidylinositol 3 (PI3) kinase pathway [72].  
 
Tauro-conjugated UDCA, TUDCA (the main species seen in humans), administered to rats 
prior to a myocardial infarction (MI) also exhibits anti-apoptotic effects and improves cardiac 
function. In a recent study TUDCA (50 mg/ml, 400 mg/kg, IV) or PBS was administered to 
rats and then the left anterior descending (LAD) coronary artery was ligated. Animals were 
sacrificed 24 hours later and a significant reduction in apoptotic cells was found in the rats 
pre-treated with TUDCA. Caspase-3 activity, an early apoptotic marker, in the TUDCA 
treated animals also decreased. In addition, transthoracic ultrasound examination of heart 
function was performed at 1 and 4 weeks post-ligation. By 4 weeks, a significantly smaller 
infarct area was present in the TUDCA group compared to the PBS group. There was also an 
improvement in shortening fraction (SF) in the TUDCA-treated animals. Therefore TUDCA 
may be considered as a viable treatment for reducing apoptosis in a model of myocardial 
infarction in rats [73].  
 
The same authors previously showed in a rodent model of acute stroke that TUDCA 
decreases brain infarct size by nearly 50% when compared to the controls [74]. This makes 
TUDCA a plausible drug for stroke treatment. TUDCA was given in a single dose (400 
mg/kg, IV) during or 1 hour after temporary ischemia-reperfusion. Two days later, the rats 
were euthanized and their brains were sectioned and stained with 2% 2,3,5-
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triphenyltetrazolium chloride (TTC). Quantitative analysis of the infarct size showed a 
significant reduction of infarct volume (49.0% in the vehicle group vs. 24.2% in the treatment 
group, p < 0.05). Furthermore, TUDCA reduced the number of TUNEL cells as compared to 
controls, indicating less DNA fragmentation [74]. 
 
TUDCA has been identified as a chemical chaperone, modulating endoplasmic reticulum 
(ER) stress and therefore acting to attenuate cardiomyopathy. A recent study by Rani et al 
found that oral administration of TUDCA in a mouse model of transverse aortic constriction 
resulted in reduction of ER stress markers and cardiac hypertrophy.  A reduction in cardiac 
apoptosis was also seen in this model after chronic administration, as well as an apparent 
reduction in cardiac remodelling including myocardial fibrosis, collagen deposition and TGF-
beta signalling [75].  TUDCA has also been shown to reverse high fat-induced alterations in 
cardiomyocyte contraction, mitochondrial permeation pore opening and phosphorylation of 
insulin signalling molecules [76].  This is in agreement with the effect of UDCA observed in 
a genetic model of obesity, the ob
-/-
 knockout mouse [77].  TUDCA has also been shown to 
attenuate angiotensin II induced abdominal aortic aneurism in apolipoprotein E deficient 
mice [78]. 
 
Cholesterol and lipoproteins (low-density lipoprotein (LDL) and high-density-lipoprotein 
(HDL)) play an important role in the development of plaques and atherosclerosis lesions. 
Since bile acid synthesis is the key route of cholesterol elimination in the body, increasing 
bile acid production by UDCA may play an important role in the prevention of 
atherosclerosis. Potential benefits have been shown for UDCA in the reduction of LDL and 
increase in HDL in both pre-clinical and clinical studies [79-81]. Coupled with the 
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cholesterol lowering and anti-inflammatory effects of UDCA, the proposed capacity of 
UDCA to act as endogenous vasodilator makes it an attractive treatment for congestive heart 
failure. Patients suffering from PBC receiving UDCA (13mg/Kg/day) over a month, showed 
a reduced diastolic volume without any systolic, diastolic or mean blood pressure change 
[82]. In a separate study in coronary artery disease patients, 6 week therapy with UDCA (13-
19mg/Kg) improved endothelium-dependent nitric oxide-independent vasodilatation [83].    
 
The effects of UDCA on endothelial function and inflammatory markers was assessed in a 
prospective, single-centre, double-blind, randomised, placebo-controlled crossover study in 
clinically stable male patients with CHF (chronic heart failure) (New York Heart Association 
functional class II/III, LV ejection fraction <45%) [84]. Patients received in random order 
500 mg UDCA twice daily for 4 weeks and placebo for another 4 weeks. The primary 
endpoint was post-ischemic peak peripheral arm blood flow as assessed by strain-gauge 
plethysmography. UDCA was well tolerated in all 16 patients that took part in the trial. 
Compared with placebo, UDCA improved peak post-ischemic blood flow in the arm (+18%, 
p = 0.038), and a trend for improved peak post-ischemic blood flow in the leg was found 
(+17%, p = 0.079). At the same time levels of γ-glutamyl transferase, aspartate transaminase, 
and soluble tumour necrosis factor-α receptor 1 were lower after treatment with UDCA than 
after placebo (all p < 0.05). This shows significant improvement of the liver function in these 
patients. However, there was no change in 6-min walk test or New York Heart Association 
functional class, and levels of TNFα and interleukin-6 were unchanged or increased 
compared with placebo. The study concluded that UDCA improves peripheral blood flow and 
liver function in patients with CHF.  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Recently, UDCA has been assessed for protecting effect against immune mediated organ 
transplant rejection. The capacity of UDCA to prolong graft survival and increase the amount 
of transplant tolerance observed in rat models has been reviewed from clinical studies with a 
significantly lower incidence in acute rejection episodes in the UDCA (500mg) group, 
compared to control [85, 86]. 
 
Taken together, evidence from pre-clinical and clinical studies show that, UDCA may be a 
novel effective therapeutic strategy in different cardiac conditions as a consequence of its 
protective effect against cell damage 
 
 
1.6 Human studies investigating the relationship between bile acids, liver disorders and 
cirrhotic cardiomyopathy 
A prolonged QT interval is the most commonly observed feature in CC.  The exact 
mechanism by which CC increases the length of the QT interval is unknown, but there is 
mounting evidence that a multitude of factors play important roles.  A study by Bernardi et al 
found that serum concentrations of CA and CDCA were significantly positively associated 
with prolongation of corrected QT (QTc) interval length suggesting that serum BAs are 
involved in this systolic defect. However serum BAs alone are not enough to act as an 
independent predictor of QTc prolongation with respect to the severity of liver disease [87].  
 
Child-Pugh scores, which are used to grade the severity of liver cirrhosis, have been shown to 
be positively associated with the likelihood of a prolonged QTc interval [88]. Child-Pugh 
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scores themselves in hepatitis-B induced cirrhosis have been significantly correlated with 
serum levels of GCA, GCDCA, TCA, TCDCA and GUDCA, and there is a potential for 
serum BAs to act as biomarkers for severity of cirrhosis [89]. 
 
Bal et al showed that 40% of their cohort of 409 patients with chronic liver disease had a 
prolonged QTc interval, which occurred more commonly in patients who had alcohol-related 
cirrhosis as well as correlating with the age and Child-Pugh score [90].  A study by Genovesi 
et al has also shown that the type of cirrhosis is concordant with the extent of QTc interval 
prolongation, as the incidence was greater in patients with alcohol induced cirrhosis in 
comparison to viral cirrhosis [91].  Differences in alcohol and non-alcohol cirrhosis is 
contradictory to Bernardi et al’s study in which no significant difference was observed [87].  
In addition to Bernardi et al, other studies have shown that the type of cirrhosis does not 
indicate the likelihood of QT interval dysfunction [92].  
 
The results of an echocardiogram study by Cichoz-Lach et al observed prolongation of the 
QTc interval, but this did not correlate with the Child-Pugh score [93]. However, cirrhosis 
was also found to significantly reduce QRS voltage, which did correlate with Child-Pugh 
classification [93]. 
 
 
1.6.1 Liver transplantation treats prolonged QT interval, however TIPS worsens it 
Liver transplantation in patients with CC appears to dramatically improve cardiac parameters, 
for example reduction of ventricular wall thickness, diastolic and systolic function as well as 
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exercise response [94].   The prolonged QTc interval in Bal et al’s cohort was normalised in 
55% of patients after liver transplantation and a similar normalisation effect was seen on a 
study of children with chronic liver disease and patients with end stage liver disease post-
orthotopic liver transplantation [95-97]. In one study, the QTc interval was shortened in 87% 
of cases after liver transplantation [90].  
 
Interestingly, this coincides with results where the gender-specific differences seen when 
examining QT intervals in normal patients (whereby healthy women have longer baseline 
QTc intervals than healthy men) have been investigated.  The differences appear to be 
abolished in cirrhotic men and women and are not restored after liver transplantation, 
suggesting that deficiency of androgens does not contribute to cirrhosis-induced QTc interval 
prolongation, although QTc interval prolongation again did not appear to correlate with the 
severity of cirrhosis [98].  This is in contrast to previous suggestions that sex hormone 
metabolism does indeed play a role [99]. 
 
Transjugular intrahepatic porto-systemic shunt (TIPS) insertion, a treatment to relieve portal 
hypertension and the accumulation of bile salts in systemic circulation (caused by portal vein 
stenosis described earlier in Zavecz and Battarbee’s experiment) was thought to be a likely 
intervention to improve prolonged QTc interval. However one study where TIPS was 
performed on cirrhotic patients with portal hypertension surprisingly had a negative effect 
and resulted in the further prolongation of QTc interval at both early (1-3 months post TIPS) 
and late (6-9 months post TIPS) observational time-points in the study, suggesting that portal 
hypertension and the resulting accumulation of cardioactive substances does not contribute to 
a prolonged QTc interval [100]. This study has a relatively small number of patients whose 
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prolonged QTc interval did not correlate with Child-Pugh score or other cirrhotic clinical 
parameters as seen in other studies. However the findings correlate with other investigations 
of QTc interval after TIPS [101].   
 
 
1.7 Diagnosis of Intrahepatic Cholestasis of Pregnancy is determined by serum bile acid 
concentrations 
Normal pregnancy is known to cause a slight elevation of maternal TSBA concentration.  
Intrahepatic Cholestasis of Pregnancy (ICP) is a disorder where the maternal TSBA 
concentration is elevated above the normal range and results in the accumulation of BAs in 
fetal serum causing an impairment in the transplacental gradient of BAs [102]. 
 
Elevated maternal TSBA concentrations of above 10µmol/L in combination with maternal 
pruritus in absence of a rash is usually considered diagnostic for ICP [103].  ICP is the most 
common pregnancy-specific liver disorder and is associated with the adverse fetal outcomes 
of fetal hypoxia, meconium staining, preterm birth and intrauterine death.  ICP is commonly 
treated with UDCA and maternal TSBA concentrations of above 40µmol/L are sometimes 
described as severe ICP and are associated with an increased risk of adverse fetal outcomes 
[103, 104].     
 
Investigation of women with mild and severe ICP compared to gestation-matched controls 
has shown a significant positive correlation between the concentration of fasting TSBA 
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concentrations and QTc interval dispersion, therefore indicating TSBA concentrations appear 
to be associated with the incidence of ventricular arrhythmia [105]. 
 
Umbilical cord blood collected from ICP patients has significantly elevated BA 
concentrations, and there is a significant reduction in the BA concentration of maternal and 
cord blood after treatment with UDCA. Whilst maternal BA profiles returned to a state 
similar to control women, UDCA had no significant effect on the composition of the fetal BA 
pool, although it did appear to increase the concentration of unconjugated BAs [102]. 
 
The RR of intrauterine death in ICP in comparison to uncomplicated pregnancy is 2.58, and it 
has been hypothesised that this risk is associated with fetal cardiac dysfunction or arrhythmia 
stemming from the increased fetal BA caused by the maternal cholestatic state [104, 106].  
Therefore, the unexplained occurrence of intrauterine death could therefore be due to a BA-
associated sudden cardiac event which has been described in several case reports summarised 
below. 
 
 
1.7.1 Case reports of fetal arrhythmia in Intrahepatic Cholestasis of Pregnancy  
It has been reported that ICP causes arrhythmias in the fetus, with UDCA treatment resulting 
in mixed outcomes. Al Inizi et al reported a patient who has been diagnosed with ICP at 37 
weeks of gestation, experiencing fetal tachyarrhythmia followed by atrial flutter after 
induction of labour.  The cardiac dysfunction ceased after the safe delivery of the fetus [107].  
In a report by Shand et al, an individual with ICP developed fetal supraventricular 
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tachycardia (SVT) at 28 weeks of gestation.  SVT is the most common form of fetal 
tachyarrythmia which may be associated with an increased mortality risk, especially in 
association with hydrops fetalis [108].  The patient was treated with anti-arrhythmic drugs 
together with UDCA and safe delivery of the fetus was achieved [109]. This is similar to a 
recent report by Altug et al, whereby an ICP patient also presented with fetal SVT. Treatment 
was with UDCA and anti-arrhythmic drugs, and SVT was only resolved after the induced 
delivery of the fetus [110]. One study of a pregnant patient who was previously diagnosed 
with PSC demonstrated that high levels of circulating TSBA concentrations in the fetus 
appears to correlate with fetal compromise, including the occurrence of fetal bradycardia 
[111].  Lee et al have reported two specific cases where raised serum BAs were observed and 
diagnoses of ICP were made. Although UDCA resulted in the decrease of TSBA 
concentrations in one case, both cases results in prolonged fetal bradycardia after onset of 
labour and ultimately observed the sudden demise of both fetuses regardless of constant fetal 
heart rate monitoring by cardiotocography (CTG) [112].  A previous case report of a patient 
diagnosed with ICP whose TSBA concentration was reduced by UDCA described sudden 
fetal demise prior to the onset of labour despite normal BA profiles and CTG monitoring 
[113].   
      
 
1.7.2 Investigations into fetal ventricular function in Intrahepatic Cholestasis of 
Pregnancy 
Doppler and Fetal ECG have been used to further investigate the fetal arrhythmia in ICP.  
Elongation of the PR interval has been reported in fetuses of patients with ICP [106].  PR 
interval elongation in fetuses is a detrimental abnormality which has been demonstrated to 
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cause arrhythmias and increase mortality risk [114, 115].  A pilot study by Strehlow et al 
demonstrated that ICP was positively associated with a significantly longer fetal mechanical 
PR interval, specifically by 14ms.  Most of the ICP mothers were being treated with UDCA 
and had a mean TSBA concentration  of 28.3µmol/L compared to 6.2 µmol/L concentration 
seen in the control group [116].  Though this study had a small sample number, similar 
findings have been observed in Rodriguez et al’s larger cohort, in which fetal PR intervals 
from patients with ICP was also significantly longer, in this case by 13ms [117].  
 
In addition to effects on the PR interval, other measures of ventricular dysfunction have been 
investigated in fetuses of patients with ICP. Ataalla et al found that fetuses of patients with 
severe ICP and TSBA concentrations of >40µmol/L had higher diastolic myocardial velocity 
as measured by tissue Doppler imaging of the right and left ventricular and septal walls [118].  
LV global longitudinal strain, (a measure of LV function), systolic and diastolic strain rate 
was found to be significantly reduced in fetuses of patients with severe ICP who had TSBA 
concentrations of >40µmol/L.  The strain rate was also correlated with levels of circulating 
N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in fetal cord blood, a 
protein that is elevated in response to left ventricular dysfunction [119].  Fetal myocardial 
performance index (MPI) also known as Tei Index is a measure systolic and diastolic 
function and was also analysed in patients with ICP.  The mean left MPI in the fetus was 
significantly positively correlated with TSBA concentration and isometric volume relaxation 
time was prolonged in patients with severe ICP, a measure which can been seen as an 
indicator of diastolic dysfunction [120]. 
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In vitro experimentation using BA administration on isolated neonatal cardiomyocytes has 
provided supporting evidence of the above clinical data and probed the effect of UDCA on 
the fetal heart.   
 
 
1.7.3 Induction of cholestasis in neonatal models of the heart and the protective effect 
of UDCA 
Primary culture of neonatal cardiomyocytes has mostly been used as a model to study the 
effect of BAs in the heart. This is the closest available in vitro model of fetal myocardium as 
these cells beat spontaneously (even in a single cell culture) and synchronously in 
clusters/monolayer [121]. TCA (0.1 – 1.0mmol/L) reduces the rate and amplitude of 
contraction, of both individual neonatal cardiomyocytes and clusters; at a higher dose (3.0 
mmol/L) cells completely stop beating [106]. The effect of TCA can be attributed to the 
direct effect of TCA on cardiomyocyte membrane depolarisation and alteration of calcium 
dynamics [122]. It is thought to be mediated, at least in part, via acetylcholine muscarinic M2 
receptor activation [7]. 
 
During development the fetal heart undergoes a ‘physiological hypoxic’ state which is 
required for  neovascularisation as well as development of other systems [123]. This hypoxic 
period leads to the conversion of fetal cardiac fibroblasts into myofibroblasts. Recently this 
conversion has been confirmed to happen in human fetal ventricular tissue during the second 
and the third trimester of gestation, the period when cholestasis-related sudden fetal death is 
most commonly occurring [124].  
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A more complex and realistic in vitro model of the fetal heart has been developed, consisting 
of a co-culture of neonatal cardiomyocytes and myofibroblasts; this model has been 
compared to sole myocyte culture which acts as a maternal heart model [116].  
 
Both acute and chronic treatment with TCA has been shown to reduce impulse propagation in 
the fetal heart model, but not in the maternal heart model. This may explain the higher 
vulnerability of the fetal heart to the exposure to high BA concentrations in ICP. In addition, 
acute treatment of TCA at 0.5 mmol/L causes early after-depolarisations, and results in 
sustained re-entrant arrhythmias (Figure 4). Interestingly, co-treatment with UDCA protects 
against the arrhythmogenic effects of TCA in the fetal heart model. These results also suggest 
that the protective effect of UDCA is more potent when myofibroblasts are present.  In this 
study, UDCA, but not TCA or other BAs, produces a substantial hyperpolarisation of 
myofibroblasts in the fetal heart model. This may be due to an increase in potassium 
conductance, as direct binding of UDCA has previously been shown to the sulfonylurea 
receptors (SURs) expressed in cardiac myofibroblasts [125]. Moreover, UDCA associates 
with several inwardly rectifying potassium ion channels (Kir) and KATP subunits [126, 127].  
 
In the fetal heart model, TCA has been shown to depolarise neonatal rat cardiac 
myofibroblasts but not cardiomyocytes [128]. Similar effects of TCA were also observed in 
human fetal cardiac fibroblasts in culture [128]. Additionally, TCA prolongs calcium 
transient duration in the rat fetal heart model and human fetal cardiomyocyte culture.  In 
contrast UDCA has been shown to hyperpolarise both rat and human fibroblasts, and abolish 
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the effect of TCA on the resting membrane potential [128]. Furthermore, treatment with 
UDCA normalises the effects of TCA on calcium propagation [128].  
 
Interestingly, UDCA was also found to suppress the transition of neonatal rat cardiac 
fibroblasts and human fetal cardiac fibroblasts into myofibroblasts in hypoxic condition, as 
seen by the expression of alpha-smooth muscle actin (α-SMA), and thus preventing fibrosis, 
as shown by repression of several fibrosis markers [128]. This suggests that UDCA may be 
useful in the treatment of fibrosis. However, further studies are needed to investigate the 
underlying mechanisms of UDCA-induced suppression of the transition of fibroblasts to 
myofibroblasts.  
 
With regard to the adverse effect of ICP on the fetal heart, most experiments have focused on 
the effects of TCA in neonatal heart models, even though elevation of other species of BAs 
(e.g., conjugated CDCA and DCA) occur in ICP (although not as markedly as TCA) [129]. 
Other BAs may negatively affect the function of the fetal heart in ICP pregnancies through 
different pathways than those described for TCA.  
 
Desai et al. (2017) has reported high BA levels switching the metabolic function of cardiac 
cells from lipid oxidation to glucose metabolism. Treatment of neonatal rat cardiomyocytes 
with CDCA (100µmol/L) for 4 hours induces remarkable suppression of FAO regulators such 
as Pgc1α, m-Cpt1, Nrf-1, Nrf-2, and Tfam, as well as Pdk4, a crucial inhibitor of glucose 
oxidation. These finding suggest other mechanisms of BA action in modulating cardiac 
functions [64].  
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The involvement of other BA receptor signalling such as pregnane-X-receptor (PXR), VDR, 
TGR5, and sphingosine 1-phosphate receptor (S1P) has not yet been determined either in 
short or long-term BA exposure towards the fetal heart during ICP.  
 
Figure 4: Example of the arrhythmia induced by taurocholic acid (TCA) in a preparation 
consisting of a monolayer of cardiomyocytes coated with a monolayer of myofibroblasts. (A) 
Optical recording of spontaneous electrical activity (45 bpm; bottom) originates from the 
periphery and propagates uniformly at 21 cm/s. (B) After acute exposure to 0.5 mmol/L, 
TCA conduction velocity (θ) was reduced from 21 to 9 cm/s. Moreover, propagated action 
potentials display EADs, where the last activation was followed by (C) self-sustained re-
entrant excitation. Frequency of rotation was 5.2 Hz. Bar = 1 mm. Blue squares in the 
overview indicate the locations of recorded traces. Red stars indicate the origins of 
spontaneous electrical activation. 
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1.8 Summary and Future Perspectives 
Previously it was assumed that the principal role of bile acids was to influence cholesterol 
catabolism and act as detergents for lipid absorption. However, increasing evidence has 
emerged for the role of BAs as hormone-like signalling molecules in a variety of 
physiological processes, one of these being normal cardiac function. 
 
Expression of BA receptors on cardiomyocytes suggests that circulating BAs have the 
potential to directly affect the heart, although the functional ability of these receptors to 
mediate BA signalling has only been confirmed to date with the FXR and M2 receptor 
pathways in in vitro cardiomyocyte cultures. 
 
Cirrhosis results in impaired BA transport and is known to cause the development of cirrhotic 
cardiomyopathy in 50% of patients. Experiments to elucidate the mechanisms of how 
cirrhosis, BAs and cardiovascular function are related have been conducted on bile duct 
ligated rats, mice and other animal models of cirrhosis.  Clinical observations of patients with 
cirrhotic cardiomyopathy together with patients with cholestatic diseases such as PBC and 
PSC have identified associations between TSBA concentration and severity of cardiac 
dysfunction. Specific analyses of the electrical conduction in the cardiac cycle have identified 
elongation of the QT interval in adults and elongation of the PR interval in fetuses to be 
associated with elevated TSBA concentrations. 
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In vitro and in vivo studies have established the clear contrast between the cardiotoxic effect 
of hydrophobic BAs and cardioprotective effect of hydrophilic BAs, thereby highlighting the 
importance of BA pool composition in cholestasis.  The investigation of the mechanisms of 
action of UDCA has provided further evidence of the importance of BA pool composition 
due to the displacement of the more hydrophobic BAs upon UDCA treatment. 
 
UDCA has been shown to improve cardiac function via a reduction in cardiomyocyte 
apoptosis and is often used as a treatment for liver disorders. TUDCA has also been shown to 
have a preventative effect on cardiac dysfunction in murine models.  Ongoing clinical trials 
investigating Obeticholic acid (OCA), a derivative of CDCA and a more potent ligand for 
FXR, have also demonstrated considerable potential to reduce markers of liver cirrhosis in 
patients with PBC and PSC however it’s specific effect on cardiac function has not been 
investigated [130]. Results from current trials using 24-norursodeoxycholic acid (norUDCA), 
a side chain shortened homologue of UDCA, have also displayed  promise to treat PSC due 
to its ability to reduce cholestatic markers [131].  It is possible that hydrophilic BAs such as 
UDCA, UDCA derivatives and OCA have the potential to be used as stand-alone treatment 
for cardiac dysfunction, although the direct effect of these bile acids on the adult and fetal 
heart requires further investigation. 
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Highlights 
- Studies show that elevated serum bile acids are associated with cardiac dysfunction 
 
- Bile acids have been implicated in the formation of cirrhotic cardiomyopathy 
 
- Bile acids with a higher hydrophobicity have an increased dysfunctional effect 
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